ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder ce… Read more
ReproCELL Incorporated (6RC) - Total Assets
Latest total assets as of September 2025: €9.36 Billion EUR
Based on the latest financial reports, ReproCELL Incorporated (6RC) holds total assets worth €9.36 Billion EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ReproCELL Incorporated - Total Assets Trend (2014–2025)
This chart illustrates how ReproCELL Incorporated’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ReproCELL Incorporated - Asset Composition Analysis
Current Asset Composition (March 2025)
ReproCELL Incorporated's total assets of €9.36 Billion consist of 50.6% current assets and 49.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.2% |
| Accounts Receivable | €463.93 Million | 4.8% |
| Inventory | €270.36 Million | 2.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €18.70 Million | 0.2% |
| Goodwill | €8.14 Million | 0.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how ReproCELL Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ReproCELL Incorporated's current assets represent 50.6% of total assets in 2025, a decrease from 98.6% in 2014.
- Cash Position: Cash and equivalents constituted 29.2% of total assets in 2025, down from 95.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 4.8% of total assets.
ReproCELL Incorporated Competitors by Total Assets
Key competitors of ReproCELL Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ReproCELL Incorporated - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ReproCELL Incorporated generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, ReproCELL Incorporated generates $ 1.07 in net profit.
ReproCELL Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.07 | 9.40 | 10.80 |
| Quick Ratio | 10.56 | 8.97 | 10.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.96 Billion | € 5.40 Billion | € 5.02 Billion |
ReproCELL Incorporated - Advanced Valuation Insights
This section examines the relationship between ReproCELL Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | €9.67 Billion |
| Market Capitalization | $67.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values ReproCELL Incorporated's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ReproCELL Incorporated's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ReproCELL Incorporated (2014–2025)
The table below shows the annual total assets of ReproCELL Incorporated from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €9.67 Billion | +6.83% |
| 2024-03-31 | €9.05 Billion | +8.34% |
| 2023-03-31 | €8.36 Billion | +3.22% |
| 2022-03-31 | €8.10 Billion | +33.86% |
| 2021-03-31 | €6.05 Billion | -7.71% |
| 2020-03-31 | €6.55 Billion | -12.51% |
| 2019-03-31 | €7.49 Billion | +13.52% |
| 2018-03-31 | €6.60 Billion | -16.00% |
| 2017-03-31 | €7.85 Billion | -1.43% |
| 2016-03-31 | €7.97 Billion | +4.92% |
| 2015-03-31 | €7.59 Billion | +40.16% |
| 2014-03-31 | €5.42 Billion | -- |